These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24066885)

  • 1. Pertussis vaccines: state-of-the-art and future trends.
    Tefon BE; Özcengiz E; Özcengiz G
    Curr Top Med Chem; 2013; 13(20):2581-96. PubMed ID: 24066885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
    Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
    Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertussis control: time for something new?
    Clark TA; Messonnier NE; Hadler SC
    Trends Microbiol; 2012 May; 20(5):211-3. PubMed ID: 22494804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen.
    Mooi FR
    Infect Genet Evol; 2010 Jan; 10(1):36-49. PubMed ID: 19879977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.
    Bart MJ; Harris SR; Advani A; Arakawa Y; Bottero D; Bouchez V; Cassiday PK; Chiang CS; Dalby T; Fry NK; Gaillard ME; van Gent M; Guiso N; Hallander HO; Harvill ET; He Q; van der Heide HG; Heuvelman K; Hozbor DF; Kamachi K; Karataev GI; Lan R; Lutyńska A; Maharjan RP; Mertsola J; Miyamura T; Octavia S; Preston A; Quail MA; Sintchenko V; Stefanelli P; Tondella ML; Tsang RS; Xu Y; Yao SM; Zhang S; Parkhill J; Mooi FR
    mBio; 2014 Apr; 5(2):e01074. PubMed ID: 24757216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roads to the development of improved pertussis vaccines paved by immunology.
    Brummelman J; Wilk MM; Han WG; van Els CA; Mills KH
    Pathog Dis; 2015 Nov; 73(8):ftv067. PubMed ID: 26347400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development.
    Preston A
    Hum Vaccin Immunother; 2016 May; 12(5):1274-6. PubMed ID: 26889694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors contributing to pertussis resurgence.
    He Q; Mertsola J
    Future Microbiol; 2008 Jun; 3(3):329-39. PubMed ID: 18505398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertussis: Where did we go wrong and what can we do about it?
    Locht C
    J Infect; 2016 Jul; 72 Suppl():S34-40. PubMed ID: 27161992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of improved vaccines against whooping cough: current status.
    Marzouqi I; Richmond P; Fry S; Wetherall J; Mukkur T
    Hum Vaccin; 2010 Jul; 6(7):543-53. PubMed ID: 20448470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
    Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine.
    Bolotin S; Harvill ET; Crowcroft NS
    Pathog Dis; 2015 Nov; 73(8):ftv057. PubMed ID: 26253079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine.
    Dunne A; Mielke LA; Allen AC; Sutton CE; Higgs R; Cunningham CC; Higgins SC; Mills KH
    Mucosal Immunol; 2015 May; 8(3):607-17. PubMed ID: 25315966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a need for a new generation of vaccines against pertussis?
    Storsaeter J; Wolter J
    Expert Opin Emerg Drugs; 2006 May; 11(2):195-205. PubMed ID: 16634696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acellular pertussis vaccines and pertussis resurgence: revise or replace?
    Ausiello CM; Cassone A
    mBio; 2014 Jun; 5(3):e01339-14. PubMed ID: 24917600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomics of Bordetella pertussis whole-cell and acellular vaccines.
    Möller J; Kraner ME; Burkovski A
    BMC Res Notes; 2019 Jun; 12(1):329. PubMed ID: 31182148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resurgence of pertussis calls for re-evaluation of pertussis animal models.
    van der Ark AA; Hozbor DF; Boog CJ; Metz B; van den Dobbelsteen GP; van Els CA
    Expert Rev Vaccines; 2012 Sep; 11(9):1121-37. PubMed ID: 23151168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis.
    Valentini D; Ferrara G; Advani R; Hallander HO; Maeurer MJ
    BMC Immunol; 2015 Jul; 16():40. PubMed ID: 26129684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating pertussis toxin and its impact on vaccination.
    Coutte L; Locht C
    Future Microbiol; 2015; 10(2):241-54. PubMed ID: 25689536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.